Key Points
- Zoetis director Michael Mccallister bought 3,000 shares of ZTS on May 11 at an average price of $77.76, a $233,280 transaction that increased his ownership by 13.94%.
- The purchase comes as Zoetis shares trade near their 52-week low, opening at $76.92, far below the 52-week high of $172.23 and well under both the 50-day and 200-day moving averages.
- Zoetis recently missed quarterly earnings and revenue estimates, reporting EPS of $1.53 versus $1.60 expected and revenue of $2.26 billion versus $2.30 billion expected, while analysts currently rate the stock a consensus Hold.
Zoetis Inc. (NYSE:ZTS - Get Free Report) Director Michael Mccallister purchased 3,000 shares of the stock in a transaction on Monday, May 11th. The stock was bought at an average price of $77.76 per share, for a total transaction of $233,280.00. Following the completion of the transaction, the director directly owned 24,524 shares of the company's stock, valued at approximately $1,906,986.24. This trade represents a 13.94% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Zoetis Price Performance
Shares of ZTS stock opened at $76.92 on Wednesday. The stock's fifty day moving average is $115.42 and its 200-day moving average is $122.28. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. The stock has a market capitalization of $32.25 billion, a PE ratio of 12.76, a PEG ratio of 1.25 and a beta of 0.87. Zoetis Inc. has a 52 week low of $75.11 and a 52 week high of $172.23.
Zoetis (NYSE:ZTS - Get Free Report) last announced its earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing the consensus estimate of $1.60 by ($0.07). The business had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.Zoetis's revenue for the quarter was up 2.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Equities research analysts expect that Zoetis Inc. will post 6.9 EPS for the current fiscal year.
Hedge Funds Weigh In On Zoetis
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Global Wealth Strategies & Associates acquired a new position in Zoetis in the 4th quarter valued at $25,000. Prosperity Bancshares Inc bought a new stake in shares of Zoetis in the 4th quarter valued at about $25,000. Cassaday & Co Wealth Management LLC bought a new stake in shares of Zoetis in the 1st quarter valued at about $28,000. Lodestone Wealth Management LLC acquired a new position in shares of Zoetis in the 4th quarter valued at about $30,000. Finally, Root Financial Partners LLC raised its stake in Zoetis by 66.5% during the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company's stock worth $30,000 after buying an additional 103 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several research firms recently issued reports on ZTS. BTIG Research reiterated a "buy" rating and issued a $160.00 price target on shares of Zoetis in a report on Thursday, February 26th. Piper Sandler reaffirmed a "neutral" rating and set a $135.00 price target (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. UBS Group dropped their price target on Zoetis from $130.00 to $99.00 and set a "neutral" rating on the stock in a research report on Friday. Weiss Ratings downgraded Zoetis from a "hold (c-)" rating to a "sell (d+)" rating in a report on Friday, March 27th. Finally, Stifel Nicolaus set a $105.00 price target on Zoetis in a research note on Friday. Seven equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $141.25.
Read Our Latest Stock Analysis on Zoetis
Zoetis Company Profile
(
Get Free Report)
Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.
Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
